Perinatal mortality · pregnant women
1 finding from 1 review
Large‐for‐gestational age · pregnant women
It is very uncertain whether low‐GI dietary advice changes large‐for‐gestational age compared with moderate‐ to high‐GI dietary advice (child outcomes) (very low certainty).
1 finding from 1 review
Mortality or morbidity composite · pregnant women
1 finding from 1 review
Neonatal hypoglycaemia · pregnant women
1 finding from 1 review
Childhood/adulthood adiposity · pregnant women
1 finding from 1 review
Childhood/adulthood type 2 diabetes mellitus · pregnant women
1 finding from 1 review
Neurosensory disability · pregnant women
1 finding from 1 review
Diagnosis of gestational diabetes · pregnant women at low or high risk of gestational diabetes
It is very uncertain whether 75 g OGTT changes diagnosis of gestational diabetes compared with 100 g OGTT (very low certainty).
1 finding from 1 review
Caesarean section · pregnant women at low or high risk of gestational diabetes
1 finding from 1 review
Macrosomia > 4.5 kg or as defined in trial · pregnant women at low or high risk of gestational diabetes
1 finding from 1 review
Long‐term type 2 diabetes maternal · pregnant women at low or high risk of gestational diabetes
1 finding from 1 review
Long‐term type 2 diabetes infant · pregnant women at low or high risk of gestational diabetes
1 finding from 1 review
Costs · pregnant women at low or high risk of gestational diabetes
1 finding from 1 review
Clinical response: no clinically significant response in mental state · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower leaving the study early ‐ any reason compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Behaviour: deterioration of behaviour (categorised as reason to leave early) · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) may leads to higher behaviour: deterioration of behaviour (categorised as reason to… compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (low certainty).
1 finding from 1 review
Adverse effects: unspecified extrapyramidal symptoms · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: unspecified extrapyramidal symptoms compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Adverse event: Death · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in adverse event: death compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to higher global state: no clinically important improvement ‐ medium term compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
1 finding from 1 review
Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · schizophrenia
1 finding from 1 review